K. Pratt

发表

Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain

H. Weiner, D. Lillicrap, C. Hough, 2006, Journal of thrombosis and haemostasis : JTH.

New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures.

K. Fujikawa, K. Pratt, P. Fuentes-Prior, 2002, Current protein & peptide science.

Dangerous liaisons: how the immune system deals with factor VIII

J. Voorberg, A. Wróblewska, B. Reipert, 2013, Journal of thrombosis and haemostasis : JTH.

T‐cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site

J. Voorberg, S. V. van Haren, E. James, 2011, Journal of thrombosis and haemostasis : JTH.

HLA‐DR‐restricted T‐cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P

E. James, W. Kwok, A. Thompson, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

P. Lenting, R. Montgomery, S. Pipe, 2016, Blood.

Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

D. Scott, S. Rieder, E. Shevach, 2015, Blood.

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies

D. Scott, K. Pratt, 2020, Frontiers in Immunology.

Engineered antigen-speci fi c human regulatory T cells : immunosuppression of FVIII-speci fi c T-and B-cell responses

D. Scott, S. Rieder, E. Shevach, 2015 .

Inhibitors—Recent insights

S. Lacroix-Desmazes, V. Arruda, K. Pratt, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19

K. Chung, A. F. Karim, S. Casares, 2021, Human vaccines & immunotherapeutics.

SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital — New York City, April 2020

C. Broder, K. Chung, F. Krammer, 2021, MMWR. Morbidity and mortality weekly report.

The humanized DRAGA mouse (HLA-A2. HLA-DR4. RAG1 KO. IL-2R g c KO. NOD) establishes inducible and transmissible models for influenza type A infections

S. Casares, T. Brumeanu, K. Pratt, 2020, Human vaccines & immunotherapeutics.

Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

K. Pratt, 2018, Antibodies.

Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.

E. James, W. Kwok, A. Thompson, 2009, Blood.

Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

M. Epstein, K. Lewis, C. Kempton, 2013, PloS one.

Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition

N. Friedman, A. Sali, P. Paz, 2018, bioRxiv.

Progress toward inducing immunologic tolerance to factor VIII.

D. Scott, C. Miao, K. Pratt, 2013, Blood.

High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

K. Lewis, S. Meeks, J. Healey, 2014, Blood.

Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site

D. Scott, K. Pratt, J. Qian, 2004, Thrombosis and Haemostasis.

Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate.

D. Scott, K. Pratt, Y. Kim, 2016, Cellular immunology.

Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies

S. Lacroix-Desmazes, K. Pratt, 2021, Frontiers in Immunology.

ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay

K. Pratt, K. Qu, M. Sahud, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia management: time to get personal?

C. Yanover, J. Mahlangu, A. Krause, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.

D. Scott, K. Pratt, Kalpana Parvathaneni, 2017, Translational research : the journal of laboratory and clinical medicine.

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators

M. Wilkerson, C. Königs, C. Dalgard, 2019, Frontiers in Immunology.

Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

M. Epstein, E. James, Janice S. Withycombe, 2014, Blood.

FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

E. James, A. Thompson, K. Pratt, 2018, Blood advances.

Factor VIII mutations in 42 Moldovan haemophilia A families, including 12 that are novel

K. Pratt, S. Nakaya, A. R. Thompson, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

B. Stoddard, J. Saint-Remy, K. Pratt, 2001, Blood.

Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.

K. Fujikawa, B. Shen, B. Stoddard, 2000, Blood.

Chain of Human Fibrinogen γ Naturally Occurring Mutations in the -Chain Dysfibrinogenemias: Molecular Structure-Function Relationships of γ

S. Lord, K. Pratt, 2013 .

γ-Chain Dysfibrinogenemias: Molecular Structure-Function Relationships of Naturally Occurring Mutations in the γ Chain of Human Fibrinogen

S. Lord, K. Pratt, H. Côté, 1998 .

identification of an inhibitory antibody epitope on the surface of factor VIII Fab complex: κ immunoglobulin G4 - Structure of a factor VIII C2 domain

B. Stoddard, J. Saint-Remy, K. Pratt, 2013 .

Sequence-Modified Factor VIII Variants Having Reduced Immunogenicity

M. Epstein, E. James, K. Pratt, 2012 .

THROMBOSIS AND HEMOSTASIS High-resolution mapping of epitopes on the C 2 domain of factor VIII by analysis of point mutants using surface plasmon resonance

K. Lewis, S. Meeks, J. Healey, 2014 .

B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses

A. Thompson, K. Pratt, 2009, Clinical reviews in allergy & immunology.

Tolerating Factor VIII: Recent Progress

D. Scott, S. Lacroix-Desmazes, J. Voorberg, 2020, Frontiers in Immunology.

T‐cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self‐peptide

E. James, W. Kwok, A. Thompson, 2007, Journal of thrombosis and haemostasis : JTH.

Inhibitory antibodies in hemophilia A

K. Pratt, 2012, Current opinion in hematology.

Engineering less immunogenic and antigenic FVIII proteins.

K. Pratt, 2016, Cellular immunology.

T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.

P. Paz, E. James, A. Thompson, 2016, Blood.

Six Amino Acid Residues in a 1200 Å2 Interface Mediate Binding of Factor VIII to an IgG4κ Inhibitory Antibody

A. Thompson, K. Pratt, Jasper C. Lin, 2015, PloS one.

Structure of the C2 domain of human factor VIII at 1.5 Å resolution

K. Fujikawa, B. Shen, B. Stoddard, 1999, Nature.

Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers.

M. Ragni, K. Pratt, Debargh Dutta, 2016, Blood advances.

A unique major histocompatibility complex Class II–binding register correlates with HLA‐DR11–associated immunogenicity of the major K blood group antigen

J. Zimring, K. Pratt, Devi Gunasekera, 2018, Transfusion.

fVIII binds platelets + fibrin: no PS!

K. Pratt, 2015, Blood.

The factor VIII C1 domain contributes to platelet binding.

A. Thompson, K. Pratt, Ting-Chang Hsu, 2008, Blood.

Crystal structure of a 30 kDa C-terminal fragment from the γ chain of human fibrinogen

E. Davie, D. Teller, V. Yee, 1997 .

The Polymerization Pocket “a” within the Carboxyl-terminal Region of the γ Chain of Human Fibrinogen Is Adjacent to but Independent from the Calcium-binding Site*

E. Davie, K. Pratt, D. Chung, 1997, The Journal of Biological Chemistry.

The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro.

E. Davie, K. Pratt, R. Stenkamp, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen.

E. Davie, D. Teller, V. Yee, 1997, Structure.

IL-17 Is Secreted by T-Cell Clones Isolated Following An Initial Peak Inhibitor Response to Factor VIIII, Suggesting Th17 Cells Play a Role in Inhibitor Development

E. James, W. Kwok, A. Thompson, 2008 .

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4+ T-effector responses to multiple epitopes in FVIII

A. F. Karim, M. Ragni, K. Pratt, 2023, Frontiers in Immunology.

A Human-Immune-System mouse model for COVID-19 research (DRAGA mouse: HLA-A2.HLA-DR4.Rag1KO.IL-2Rγc KO.NOD)

K. Chung, A. F. Karim, S. Casares, 2020, bioRxiv.

Marginal immunogenicity of factor VIII.

K. Pratt, 2017, Blood.

gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen.

S. Lord, K. Pratt, H. Côté, 1998, Blood.

A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19

Ian J. Stewart, Jeffrey T. Howard, J. Dellavolpe, 2022, Critical care explorations.

A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report

Ian J. Stewart, K. Sharma, J. Dellavolpe, 2021, medRxiv.

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers

D. Scott, C. Broder, J. Powers, 2021, BMC Infectious Diseases.

Covalent Inactivation of Factor VIII Antibodies from Hemophilia A Patients by an Electrophilic FVIII Analog*

E. Donnachie, K. Pratt, M. Escobar, 2008, Journal of Biological Chemistry.

Idiotype-mediated neutralization of factor VIII inhibitor antibodies

K. Pratt, 2004 .

Deletion of residue Ala2201 in the Factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by Factor VIII inhibitor antibodies

B. Stoddard, J. Vermylen, K. Peerlinck, 2001 .

A Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO.IL-2Rγc KO. NOD) for COVID-19

K. Chung, A. F. Karim, S. Casares, 2020, bioRxiv.

The Immune Response to the fVIII Gene Therapy in Preclinical Models

H. Spencer, C. Doering, K. Pratt, 2020, Frontiers in Immunology.

New predictive approaches for ITI treatment

C. Königs, E. Santagostino, C. Königs, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Prevention of Anti-FVIII Inhibitor Formation Post Protein Infusion in Hemophilic Mice by Prior Feeding of the FVIII-C2 Domain.

E. Davie, D. Lillicrap, F. E. Rawle, 2004 .

Title Endogenous factor VIII synthesis from the intron 22-inverted F 8 locus may modulate the immunogenicity of replacement therapy for hemophilia

Yasmin, C. Yanover, T. Przytycka, 2014 .

Factor VIII forges its own path.

K. Pratt, 2023, Blood.

Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized Controlled Trial of Ivabradine for Those With Postural Orthostatic Tachycardia Syndrome (The COVIVA Study)

C. Dalgård, M. Haigney, M. Tanofsky-Kraff, 2023, medRxiv.

Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition

N. Friedman, A. Sali, P. Paz, 2018, bioRxiv.

High-Resolution Mapping of B-Cell Epitopes on the Factor VIII C2 Domain Using Surface Plasmon Resonance

K. Lewis, S. Meeks, J. Healey, 2011 .